Madrigal Pharmaceuticals, Inc. (MDGL) short interest & options flow
NASDAQMadrigal Pharmaceuticals enters the final week of September with a fresh analyst initiation pulling in one direction and a month-long rise in short positioning pulling in the other. Citi's Eric Joseph launched coverage this week with a Buy rating and a $725 target — the most timely piece of analyst activity on MDGL right now. The broader Street is constructively aligned: 14 buys, a…
MDGL short interest plunged 41% over one week to 8.6% of float, as shorts exited ahead of earnings. Availability surged to 1,409%, signaling minimal squeeze risk.
- Market cap
- $9.31B
- Next earnings
- 16 Feb 2027
Key data as of 5 Nov 2026
Latest signals on MDGL
- Short Interest
MDGL short interest plunged 41% over one week to 8.6% of float, as shorts exited ahead of earnings. Availability surged to 1,409%, signaling minimal squeeze risk.
- Cost to Borrow
MDGL cost to borrow explodes 442% in one week to 1.98%, as short interest declines to 16% of float amid tight availability.
MDGL news and analysis
RSSNo long-form analysis yet for MDGL. Pulse alerts and the live data picture are available on ORTEX.
Open MDGL on ORTEX →Want the live picture for MDGL?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MDGL — free to start on ORTEX.
Sign up for free →Open MDGL on ORTEX